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Abstract
We recently associated ovarian FMR1genotypes and sub-genotypes with distinct ovarian aging patterns. How they impact
older females is, however, unknown. We, therefore, investigated 217 consecutive first in vitro fertilization (IVF) cycles in
women .40 assessing oocyte yields, stratified for better (anti-Mu ¨llerian hormone, AMH .1.05 ng/mL) or poorer
(AMH#1.05 ng/mL) functional reserve (FOR)). Mean age was 42.462.0 years, mean AMH 0.7660.92 ng/mL and mean
oocyte yield 5.365.4. Overall, and in women with better FOR, FMR1 did not affect oocyte yields. With poorer FOR
(AMH#1.05 ng/mL) women with het-norm/high, however, demonstrated higher oocyte yields (5.063.8) than those with het-
norm/low sub-genotype 3.162.5; P=0.03), confirmed after log conversion. Known associated with low FOR at young age,
het-norm/high, thus, appears to preserve FOR into older age, and both het sub-genotypes appear to expand female
reproductive lifespan into opposite directions.
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Introduction
Based on a normal range of CGG polynucleotide repeats of 26 to
34 (median 30), we recently reported ovarian genotypes and sub-
genotypes of the FMR1 gene, so named because of their association
with distinct ovarian aging patterns [1–3]. They have to be
differentiated from previously reported FMR1 genotypes, clinically
widely utilized to define neuro-psychiatric risks, associated with triple
CGGn expansions to traditional premutation and full mutation
genotype ranges [4]. Expanded CGGn beyond 34 repeats would
under the ovarian genotype nomenclature represent so-called high sub-
genotypes of either heterozygous (het) or homozygous (hom) genotypes
(see Materials and Methods for further detail). Probably because never
before associated with pathology, traditional FMR1 genotypes do not
address abnormally low CGGn counts, though they have been
included in the ovarian genotype nomenclature as low ovarian sub-
genotypes, and have been associated not only with distinct ovarian
aging patterns but also with increased autoimmune risk [1–3].
Especially the so-called het-norm/low FMR1 sub-genotypes has
been strongly associated with a specific ovarian aging pattern,
characterized by abundant follicle recruitment and, therefore,
excessive functional ovarian reserve (FOR) at young age, and also
with autoimmunity [2]. These associations occur in all races/
ethnicities, though with varying prevalence [3]. Because of very
active follicle recruitment at young age, het-norm/low women rather
quickly deplete their FOR, often demonstrating already at young
ages abnormally diminished ovarian reserve [2].
In comparison to other FMR1 genotypes and sub-genotypes, one,
therefore, can view het-norm/low as moving a woman’s functional
reproductive peak towards younger ages. How ovarian FMR1
genotypes and sub-genotypes affect ovarian reserve at older female
age is still not well understood, and was subject of investigation in this
study.
Materials and Methods
Assuming identical ovarian aging patterns, women with
different FMR1 genotypes and sub-genotypes should demonstrate
similar FOR at advanced ages. FOR can be assessed in various
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with in vitro fertilization (IVF), likely, best reflect FOR [5]. In
addition, FOR can, of course, also be defined by follicle
stimulating hormone (FSH) [6], anti-Mu ¨llerian hormone (AMH)
[7] and antral follicle counts [8].
Patients
We investigated 217 consecutive first IVF cycles in women
above age 40 and assessed, as previously reported [1–3], oocyte
yields in association with different FMR1 genotypes and sub-
genotypes. In brief, the CGGn was determined for each patients,
utilizing different laboratories, depending on insurance coverage
(Genzyme Analytical Services, Westborough MA; Quest Diagnos-
tics, Lyndhurst, NJ; and LabCorp, Burlington, NC). We previously
determined that all laboratories used identical techniques, and
found results compatible. Results were reported as number of triple
CGG repeats per allele.
Utilizing test results from all of these laboratories, we previously
reported that in regards to ovarian function, the normal range of
CGG repeats on FMR1 is 26–34 (median 30) [1]. This median also
corresponds to the reported switching point between positive and
negative message, as well as peak translation [9].
Based on this normal range, a woman can be normal (norm)i f
both of her alleles are in normal range, can be heterozygous (het)i f
one allele is in and one out of range, and homozygous (hom) if both
alleles are out of range [1]. Het and hom patients can be further
sub-divided into sub-genotypes, depending whether their abnor-
mal count allele is above (high) or below (low) normal range. Het
women, thus, can be het-norm/high and het-norm/low; hom women
can be het-high/high, het-high/low or het-low/low [2,3]. Because, as
here again confirmed, hom patients are apparently very rare
amongst infertility patients, the very few hom patients in this patient
population were excluded from consideration. This study,
therefore, only reports on associations of norm and het genotypes
on FOR at advanced female ages.
FOR was definedbylevelsof AMH,as repeatedlybeforereported
[7], and by oocyte yields in routine IVF cycles. Only first IVF cycles
wereanalyzed.Sinceallpatientswereaboveage40years,theyatour
center are automatically considered to suffer from diminished FOR.
This means that all patients receive ovarian stimulation through a
microdose agonist protocol, utilizing an FSH product (300–450 IU)
and a human menopausal gonadotropin (hMG) product (150 IU)
daily. Products from different manufacturers were prescribed, based
on the patient’s insurance requirements.
All patients were managed by two senior physicians (N.G. and
D.H.B.) who in their respective patient outcomes, based on years
of comparative quality control evaluations, do not differ in regards
to numbers of oocytes retrieved or pregnancy rates in IVF cycles.
Both physicians utilize identical patient protocols. Such differences
are considered the principle cause for inaccuracies in utilizing
oocyte yields as reflections of FOR [5].
As all patients suffered because of their age from low FOR, they,
based on AMH levels, were sub-divided into those with poorer
pregnancy prognosis (AMH,1.05 ng/mL and better pregnancy
chances (AMH$1.05 ng/mL). We previously reported that this
AMH cut off, at all ages, discriminates between lower and higher
pregnancy chances in women with low FOR [10].
All women with low FOR are at our center automatically
supplemented with dehydroepiandrosterone (DHEA) (25 mg TID)
for at least six weeks prior to IVF cycle start [11]. Here presented
cycle outcome data are, therefore, not necessarily applicable to
other women with low FOR, who are not DHEA supplemented.
Statistical analysis
FMR1 genotypes are reported as counts (%), while all other
variables are reported as means 6 standard deviation. Cancelled
cycles (n=20) are counted as 0 eggs.
Differences between normally distributed variables were tested
with analysis of variance. Differences between groups of variables
not conforming to normality were tested for with the Mann-
Whitney test. A P of ,0.05 was considered statistically significant.
Statistical analyses were performed using the Statistical Package
for Social Science version 18.0 (SPSS Inc., Chicago, IL)
Institutional Review Board
Reported data were extracted from the center’s anonymized
electronic research database, and, where necessary, supplemented
by individual chart reviews. All of the center’s patients sign at time
of initial presentation an informed consent, which allows the study
of their medical records for research purposes as long as the
patient’s anonymity is preserved and the medical record remains
confidential. If both conditions are met, studies require only
expedited review under the center’s Institutional Review Board
(IRB) rules. Both conditions were met for this study. In addition,
all of the center’s research staff is in writing committed to
confidentiality under federal HIPAA rules.
Results
The 217 women undergoing their first IVF cycles were on
average age 42.462.0 years old. Their mean AMH was
0.7660.92 ng/mL, and mean oocyte yield was 5.365.4 (Table 1).
In assessing distribution of FMR1 genotypes and sub-genotypes,
126/217 (58.1%) were norm, 35 (16.1%) were het-norm/high, and 56
(25.8%) were het-norm/low.Inorder,norm,het-norm/highandhet-norm/
low patients produced 5.265.2, 6.166.1 and 5.065.3 oocytes, a not
significant difference; and in same order, AMH values were
0.8160.89 ng/mL, 0.8961.0 ng/mL and 0.8460.91 ng/mL, also
a non-significant difference.
Once patients were, however, assessed based on degree of
diminished FOR, differences became apparent: While oocyte
yields still did not differ among FMR1 genotypes and sub-
genotypes in women with better ovarian reserve (AMH$1.05 ng/
mL), women with poorer FOR (AMH,1.05 ng/mL) demonstrat-
ed significantly higher oocyte yields with het norm/high FMR1 sub-
genotype (5.063.8) than with het-norm/low sub-genotype (3.162.5,
P=0.03; Figure 1). Log-conversion, and adjustment for age
maintained significance.
As Figure 1 demonstrates, norm patients fell in their oocyte yields
between the two het sub-genotypes.
Table 1. Patient characteristics.
FMR1 genotype and sub-genotype
Total norm het-norm/high het-norm/low
Patients/cycles 217 126 (58.1%) 35 (16.1%) 56 (25.8%)
Age (years) 42.462.0 42.562.0 41.962.0 42.462.1
AMH (ng/mL) 0.7660.92 0.8160.89 0.8961.0 0.8460.91
Oocyte yield (n) 5.365.4 5.265.2 6.166.1 5.065.3
None of the parameters reported in this table differed significantly between the
different FMR1 genotypes and sub-genotypes. Once patients were, however,
separated into poorer (AMH#1.05 ng/mL) and better FOR (AMH.1.05 ng/mL),
differences became apparent (Figure 1).
doi:10.1371/journal.pone.0033638.t001
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Here presented study, once again, demonstrates that ovarian
aging patterns differ, depending on ovarian FMR1 genotypes and
sub-genotypes. We previously in cross-sectional studies demon-
strated distinct differences between norm and het ovarian genotypes
[1] and between het sub-genotypes [2,3]. Because hom genotypes
and sub-genotypes are rare, they have not, yet, been well defined.
These ovarian genotypes and sub-genotypes have to be
distinguished from classical FMR1 genotypes, which for decades
have been used to, primarily, define neuro-psychiatric risks with
premutation range (55–200 CGG repeats) and full mutation
(fragile X syndrome) genotypes (.200 CGG repeats) [4].
As the only not neuro-psychiatric complication of the classical
premutation genotype, the FMR1 gene has for decades also been
known associated with increased risk for premature ovarian failure
(POF) [12], now also frequently called primary ovarian insuffi-
ciency (POI). It was this association that made us suspect that the
gene may, possibly, also have ovarian functions [11].
This suspicion was further strengthened when, upon reviewing
the published literature, we came across a study of CGG
distribution in a general populationby Fu et al, which demonstrated
a very significant distribution peakat 29–30 repeats [13]. Moreover,
Chen et al had reported that 30 repeats represented the switching
point forpositivemessage andpeak translation forthe gene product,
fragile X mental retardation protein [9].
Utilizing our own infertile patients, we determined a normal
range of 26–34 CGG repeats in regards to the gene’s ovarian
function, with 30 repeats representing the median [1]. Range and
median were identified as identical in different ethnicities/races
[14]. Based on this normal range, we then defined patients as norm,
het or hom, depending whether both, one or none of their two
alleles were in normal range [1]. Moreover, het and hom genotypes
could then be sub-divided, based on whether abnormal alleles
were above (high) or below (low) the normal range [2,3].This
revealed distinct differences between het-norm/high and het-norm/low
sub-genotypes [2]: Het-norm low is at young age associated with a
polycystic ovary (PCO)-like ovarian phenotype, which rapidly
depleted its ovarian reserve, at mid-age often already leading to
prematurely diminished FOR. The sub-genotype was also
associated with autoimmunity but this association, remarkably,
reached approximately 90 percent when the sub-genotype was
associated with a PCO-like ovarian phenotype. In contrast, the het-
norm/high sub-genotype proved almost protective for autoimmuni-
ty, with only, barely, a 10 percent prevalence [2].
A further discussion of autoimmune findings exceeds the
framework of this manuscript. The reviewer is directed to another,
recent publication [15]. Clinically most relevant for infertility
practice, het-norm/low was also associated with significantly
diminished IVF pregnancy rates in comparison to norm women,
with het-norm/high patients falling in the middle [2].
Trying to understand the possible mechanisms behind this
difference in pregnancy rates, we confirmed their association with
the different ovarian genotypes and sub-genotypes in different
ethnicities/races, which demonstrate greatly varying distributions
of these genotypes and sub-genotypes, and, accordingly, also
different IVF pregnancy chances and autoimmune prevalence [3].
Here, in this study, we attempted to better define the impact of
female age. By investigating 217 consecutive first IVF cycles in
women above age 40 years, the study offers a robust sample size of
older women, seeking fertility treatment. Women at that age,
universally, can be considered to suffer from low FOR [6]. At our
center they, therefore, are routinely supplemented for at least six
weeks with DHEA before an IVF cycle is initiated [11]. Here
presented data for this reason have to be interpreted with caution
since they may not be applicable to non-supplemented IVF cycles
in older women.
We previously reported that an AMH level of 1.05 ng/mL in
women with diminished FOR defines at all ages a cut off between
better and poorer IVF pregnancy chances [10]. Here presented
results expand on these observations, as they demonstrate that in
older women, above age 40 years, their FMR1 genotypes and sub-
genotypes matter little in regards to oocyte yields in IVF, as long as
they still have minimally fair ovarian reserve, defined as an AMH
of $1.05 ng/mL. Since pregnancy chances usually follow oocyte
yields, it appears likely that pregnancy chances also will not differ
with different FMR1 genotypes and sub-genotypes, as long as
AMH levels are $1.05 ng/mL, though this fact remains to be
confirmed, as here studied cycle volume was too small to assess
pregnancy outcomes.
Below AMH of 1.05 ng/mL, FMR1 genotypes and sub-
genotypes, however, suddenly do to a significant degree matter:
It does not surprise that the het-norm/low sub-genotype, once again,
is associated with low oocyte yields, therefore, low FOR and,
likely, lower pregnancy chances with IVF. We previously reported
lower IVF pregnancy chances in association with IVF [3]. The
here observed unusually excellent performance of older women
with het-norm/high sub-genotypes, despite very poor FOR, however,
does somewhat surprise.
In a general infertility population, IVF pregnancy rates with het-
norm/high sub-genotype were observed approximately half way
between norm (best rates) and het-norm/low patients (worst rates) [2].
Here, amongst women above age 40 years, oocyte yields in het-
norm/high women outperformed both, norm (second-best) and het-
norm/low patients (worst, Figure 1).
This represents a second observed instance in which the two
ovarian het FMR1 sub-genotypes perform at opposing clinical
extremes: A similar opposing association between the two het sub-
genotypes was previously seen in definition of an autoimmune
phenotype, when het-norm-high appeared protective and het-norm/
low strongly enhancing for risk towards autoimmunity [2].
Figure 1. Oocyte yields in association with FMR1 genotypes and
sub-genotypes. Here presented data exclude 20 cancelled cycles, and,
therefore, represent 23 het norm/high and 33 het-norm/low women for
statistical comparison. Including 9 cancelled cycles in these two sub-
genotypes, the comparison maintains significance (P=0.03). It also
maintains significance using the independent samples Mann-Whitney U
test (data not shown).
doi:10.1371/journal.pone.0033638.g001
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opposing phenotypes allows for speculation: One could assume
that the original FMR1 gene only contained what, now, represents
the norm genotype. This genotype favors reproduction at relatively
young age, when, due to robust recruitment of primordial follicles,
FOR is high. Because of active recruitment, women with the norm
genotype, therefore, deplete their FOR a relatively young ages [1].
Their reproductive lifespan, consequently, would have to be
homogenous and rather short.
Preservation of the species would, likely, favor less homogenous
and, therefore, overall longer reproductive lifespans. One,
therefore, could further speculate that evolution would favor gene
mutations, which within a community allow for diversity of
reproductive lifespans, some extending towards younger and
others towards older age.
Here presented data are potentially supportive of the hypothesis
that, amongst all FMR1 genotypes and sub-genotypes, the het-
norm/high sub-genotype appears to preserve FOR into advanced
female age the best. In contrast, as noted earlier, het-norm/low is
associated with rapid depletion of FOR at young age and
prematurely low FOR [2].
Both of these sub-genotypes could, thus, be seen as mutations
from an originally norm range FMR1 gene, with the evolutionary
goal to expand the community’s reproductive lifespan into both
directions, towards younger age with het/norm/low mutations, and
towards older age with het-norm/high sub-genotypes.
While, thus, hypothetically advantageous to preservation of the
species, both mutations also result in highly disadvantageous
phenotypes to the human species: As already noted before,
abnormally low CGG counts, represented by het-norm/low,
significantly increase the risk towards autoimmunity [2,3],
potentially explaining why women carry a many-fold higher risk
[16]. Het-norm/high FMR1 mutations, by veering into CGG repeats
above norm, create potential neuro-psychiatric risks, if expansion
sizes reach classical premutation and full mutation ranges [4,12].
This study, thus, offers an expansive hypothetical view of the
importance of the FMR1 gene, which until recently almost
exclusively was only known for its neuro-psychiatric risks.
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